Opinion
Massachusetts voter Scott Edward Anderson reflects on why Ballot Question 4, the Legalization and Regulation of Psychedelic Substances Initiative, failed to pass — and what’s next.
A minister explores the spiritual and communal dimensions of psychedelics as sacred sacraments, offering a transformative alternative to clinical frameworks.
Therapist Charles Wininger offers an elder’s perspective on how to approach the election and its aftermath from a psychedelic point of view.
Beatriz Labate, Ph.D and Henrique Antunes, Ph.D. offer insights into critical dialogues about psychedelics between the Global North and Global South and diverging perspectives on the “Psychedelic Renaissance.”
Bay State author and psychedelic-assisted therapy advocate Scott Edward Anderson argues that Ballot Measure 4 establishes new models that prioritize healing, innovation, and compassion.
In part one of a series of articles on ibogaine clinics, researcher Leonard Pickard looks at the history and treatment protocols of clinics in Mexico, Brazil and Portugal.
Elizabeth Nielson, co-founder of Fluence, offers thoughts on the roll out of the 2025 psychedelic therapy program in Colorado and the opportunities it offers for mental health professionals.
In the wake of the FDA’s rejection of Lykos Therapeutics’ proposal for MDMA-Assisted therapy for PTSD, a therapist advocates for wider access to ketamine-assisted psychotherapy.
A trauma survivor’s experience with ketamine may offer new avenues for understanding the complex relationship between physical pain and mental health.
The death of Matthew Perry shows that the standard of care for clinical practice with ketamine should not include reintroducing those with a prior history of dependence and addiction to resumption of ketamine use.
